Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.
Verastem Oncology has raised $90.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in November 2025.
Verastem Oncology's investors include Bessemer Venture Partners, Oxford Finance LLC, Hercules Capital, OrbiMed, RTW Investments.
Verastem Oncology is headquartered in Needham, United States.
Verastem is a biopharmaceutical company developing new medicines to improve the lives of patients with RAS/MAPK pathway-driven cancers.
Verastem Oncology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Verastem Oncology — Funding & Investors." VCBacked, November 14, 2025, https://www.vcbacked.co/company/verastem-oncology. Accessed September 29, 2026.
VCBacked. (2025). Verastem Oncology — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/verastem-oncology
{{cite web |title=Verastem Oncology — Funding & Investors |url=https://www.vcbacked.co/company/verastem-oncology |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated